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in Rwanda: a time-series analysis
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Summary
Background In May, 2012, Rwanda became the ﬁ rst low-income African country to introduce pentavalent rotavirus 
vaccine into its routine national immunisation programme. Although the potential health beneﬁ ts of rotavirus 
vaccination are huge in low-income African countries that account for more than half the global deaths from 
rotavirus, concerns remain about the performance of oral rotavirus vaccines in these challenging settings.
Methods We conducted a time-series analysis to examine trends in admissions to hospital for non-bloody diarrhoea in 
children younger than 5 years in Rwanda between Jan 1, 2009, and Dec 31, 2014, using monthly discharge data from 
the Health Management Information System. Additionally, we reviewed the registries in the paediatric wards at six 
hospitals from 2009 to 2014 and abstracted the number of total admissions and admissions for diarrhoea in children 
younger than 5 years by admission month and age group. We studied trends in admissions speciﬁ c to rotavirus at one 
hospital that had undertaken active rotavirus surveillance from 2011 to 2014. We assessed changes in rotavirus 
epidemiology by use of data from eight active surveillance hospitals.
Findings Compared with the 2009–11 prevaccine baseline, hospital admissions for non-bloody diarrhoea captured by 
the Health Management Information System fell by 17–29% from a pre-vaccine median of 4051 to 2881 in 2013 and 
3371 in 2014, admissions for acute gastroenteritis captured in paediatric ward registries decreased by 48–49%, and 
admissions speciﬁ c to rotavirus captured by active surveillance fell by 61–70%. The greatest eﬀ ect was recorded in 
children age-eligible to be vaccinated, but we noted a decrease in the proportion of children with diarrhoea testing 
positive for rotavirus in almost every age group.
Interpretation The number of admissions to hospital for diarrhoea and rotavirus in Rwanda fell substantially after 
rotavirus vaccine implementation, including among older children age-ineligible for vaccination, suggesting indirect 
protection through reduced transmission of rotavirus. These data highlight the beneﬁ ts of routine vaccination against 
rotavirus in low-income settings.
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Introduction
Rotavirus accounts for more than a third of diarrhoea 
deaths in children younger than 5 years worldwide, with 
more than half of these deaths happening in sub-Saharan 
Africa.1 In response to this large disease burden, two live 
attenuated, orally taken rotavirus vaccines (RotaTeq 
[RV5], Merck Vaccines, Whitehouse Station, NJ, USA, 
and Rotarix [RV1], GSK Biologicals, Rixensart, Belgium)2 
are recommended by WHO for use in all countries and 
especially in those with high mortality caused by 
diarrhoea.2 By September, 2015, 79 countries had 
introduced one or other of these rotavirus vaccines.3 Most 
countries that introduced the vaccine early were high-
income and middle-income countries in the Americas 
and Europe, and these countries have provided much of 
the early evidence of the substantial eﬀ ect of rotavirus 
vaccination. In Mexico, where rotavirus vaccine was 
introduced nationally in 2007, all-cause diarrhoea deaths 
in children younger than 5 years of age fell by 35–50% 
during 2008–11.4–6 Similar decreases of 17–39% in Brazil 
and 50% in Panama were documented after rotavirus 
vaccine introduction.7–9 Additionally, many other 
countries have noted a substantial reduction in the 
number of hospital admissions for all-cause diarrhoea 
and rotavirus after the rotavirus vaccine introduction.7,10–30
Live oral vaccines, including those for rotavirus, have 
had poor performance in developing country settings.31–40 
Although the reasons for this lower performance are 
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unknown and probably complex, possible explanations 
could be interference by maternal antibodies, concurrent 
oral polio vaccine admin istration, prevalent viral and 
bacterial gut infections, and malnutrition.41 Clinical trials 
for both the available rotavirus vaccines done in Africa and 
Asia showed modest eﬃ  cacy (50–70%) compared with the 
high eﬃ  cacy (85–98%) that was recorded in trials in Latin 
America, the USA, and Europe.42–46 In view of the 
substantial disease burden in Africa and Asia, the absolute 
burden of severe diarrhoea disease prevented in these 
settings is expected to be substantial even with moderately 
eﬃ  cacious vaccines, but concerns remain about vaccine 
performance in these high burden settings.44
In May, 2012, Rwanda became the ﬁ rst low-income 
country in Africa to introduce RV5 into its routine 
expanded programme on immunisation, with three 
doses given to infants at 6, 10, and 14 weeks of age. 
Rotavirus vaccine coverage in children younger than 
1 year of age increased quickly to 50% in 2012, 99% in 
2013, and 98% in 2014.47 To monitor the eﬀ ect of 
rotavirus vaccine in Rwanda, we studied trends in the 
number of hospital admissions for diarrhoea and 
rotavirus before and after the introduction of the 
rotavirus vaccine.
Methods
Trends in hospital admissions for diarrhoea
To assess trends in hospital admissions for diarrhoea 
nationally, we reviewed data from the Health 
Management Information System, which electronically 
captures monthly data for discharges from heath facilities 
in Rwanda.48 Data are reported to the national level using 
predeﬁ ned discharge categories. We restricted our 
analysis to district hospitals that reported the number of 
hospital admissions for diarrhoea with or without 
dehydration in children younger than 5 years of age for 
every month from Jan 1, 2009, to Dec 31, 2014. We 
excluded children admitted with bloody diarrhoea and 
diarrhoea caused by chronic opportunistic infections as 
reported by the hospital. 
To supplement Health Management Information 
System data, at four district hospitals (Kabgayi District 
Hospital, Muhima District Hospital, Musanze District 
Hospital, and Rwamagana District Hospital) and two 
teaching hospitals (University Teaching Hospital Kigali, 
University Teaching Hospital Butare), we reviewed the 
registries in the paediatric wards from Jan 1, 2009, to 
Dec 31, 2014, and abstracted the total number of admissions 
to hospital and the number of admissions to hospital for 
diarrhoea in children younger than 5 years by month of 
admission and age group (age <1 year vs 1–4 years).
Trends in rotavirus-speciﬁ c hospital admissions and 
changes in rotavirus epidemiology
Active, sentinel surveillance for rotavirus diarrhoea 
following the standard WHO protocol49 started in 
September, 2010, at one large urban referral hospital in 
Kigali, Rwanda, and was subsequently expanded to four 
additional hospitals (Kibagabaga District Hospital, 
Musanze District Hospital, Rwamagana District Hospital, 
and University Teaching Hospital Butare). In September, 
2012, rotavirus surveillance was started at three more 
district hospitals (Kabgayi District Hospital, Kabutare 
District Hospital, and Muhima District Hospital), 
bringing the number of hospital surveillance sites to 
eight. Brieﬂ y, children younger than 5 years who 
presented to a sentinel hospital and met the case 
deﬁ nition for diarrhoea (occurrence of three or more 
episodes of diarrhoea [stools of a less formed character 
than usual] within a 24 h period that began fewer than 
7 days before the hospital visit) were enrolled and a stool 
specimen was collected within 48 h of admission to avoid 
detection of nosocomial infections. Stool specimens were 
refrigerated until testing for rotavirus antigen by enzyme 
immunoassay at the University Teaching Hospital Kigali 
laboratory, Kigali, Rwanda. Trends in rotavirus-speciﬁ c 
admissions to hospital were studied at one hospital that 
had done surveillance continuously from Jan 1, 2011, 
through Dec 31, 2014, under technical supervision and 
support of WHO. Changes in rotavirus epidemiology 
Research in context
Evidence before this study
We searched PubMed for articles published since 2000 in any 
language using the terms “rotavirus” and “vaccine” and 
“sub-Saharan Africa” and “impact OR eﬀ ectiveness”. Of the 
42 articles identiﬁ ed, two articles examined the eﬀ ectiveness of 
rotavirus vaccine in routine use in South Africa and Malawi and one 
study assessed the eﬀ ect of rotavirus vaccine on disease burden in 
South Africa. We found no reports of the eﬀ ect or eﬀ ectiveness of 
rotavirus vaccine in Rwanda or of the eﬀ ect or eﬀ ectiveness of 
pentavalent rotavirus vaccine in sub-Saharan Africa.
Added value of this study
This study provides the ﬁ rst evidence of the eﬀ ect of 
pentavalent rotavirus vaccine on the severe all-cause and 
rotavirus diarrhoea disease burden in sub-Saharan Africa after 
introduction of the vaccine into the routine childhood 
immunisation programme. Diarrhoea and rotavirus-speciﬁ c 
hospital admissions in Rwanda fell substantially after rotavirus 
vaccine implementation, including among older children 
age-ineligible for vaccination, suggesting indirect protection 
through reduced transmission of rotavirus.
Implications of all the available evidence
Our ﬁ ndings support the continued use of rotavirus vaccine in 
Rwanda and highlight the beneﬁ ts of routine vaccination 
against rotavirus in low-income settings.
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including changes in the proportion positive and in the 
age distribution of rotavirus positive cases were assessed 
using data from all eight surveillance hospitals.
Statistical analysis
To predict the monthly incidence of all-cause diarrhoea 
hospital admissions that would be expected to happen if 
rotavirus vaccine had not been introduced, we did a time-
series analysis. Because Poisson models showed 
overdispersion, we ﬁ tted a negative binomial model to 
the prevaccine Health Management Information System 
data for all-cause diarrhoea hospitalisation and adjusted 
for seasonality by including calendar month and for 
secular trends by including calendar year. We assessed 
model ﬁ t with the Pearson χ² statistic. We then plotted 
the expected number of hospital admissions for diarrhoea 
against the number of recorded admittances. To calculate 
the percentage reduction in the recorded number of all-
cause diarrhoea hospital admittances and associated 
95% conﬁ dence intervals (CIs) relative to the expected 
Figure 1: Hospital admissions for diarrhoea before rotavirus vaccine introduction (2009–11) and after rotavirus vaccine introduction (2013 and 2014)
(A) Predicted and observed number of hospital admissions for diarrhoea by month. (B) Number of hospital admissions for diarrhoea before rotavirus vaccine 
introduction (2009– 11) and after rotavirus vaccine introduction (2013, 2014). Data (range; min –max) for children younger than 5 years at 24 district hospitals that 
continuously reported to Health Management Information System, January, 2009, to December, 2014.
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number, we included an indicator for the time after 
rotavirus vaccine introduction in a model including 
prevaccine and post-vaccine introduction data while 
controlling for seasonal and secular trends. We 
exponentiated the β of the indicator variable and its 
associated Wald 95% CI to work out the percentage 
reduction associated with vaccine introduction. We used 
χ² tests to compare the proportion of total admissions to 
hospital because of diarrhoea for the registry review and 
the proportion of admissions for diarrhoea because of 
rotavirus in the active surveillance data before and after 
the rotavirus vaccine introduction. To compare the 
number of hospital admissions because of rotavirus 
before and after the introduction of the rotavirus vaccine 
using the rotavirus surveillance data for the continuously 
reporting hospital from 2011 through 2014, we used a 
Wilcoxon rank sum test to compare the number of 
hospital admissions per month before (2011) and after 
(2013 and 2014) rotavirus vaccine introduction. Because 
rotavirus vaccine was introduced in May, 2012, we 
regarded 2012 as a transition year with rapidly changing 
vaccine coverage, and excluded 2012 data from the post-
vaccine introduction analyses.
Analyses were done in SAS (version 9.3). The protocol 
was approved by the National Ethics Committee of 
Rwanda.
Role of the funding source
The Gavi, the Vaccine Alliance had no role in study 
design, data collection or analysis, data interpretation, or 
writing of the report. The Government of Rwanda 
provided in-kind support through staﬀ  time and logistics. 
Ministry of Health staﬀ  were involved in the study 
design, data collection, data interpretation, and writing of 
the report. All authors had full access to the data and take 
full responsibility for the integrity of the ﬁ ndings.
Results
24 of 46 district hospitals reported the number of hospital 
admissions for diarrhoea captured by the Health 
Management Information System every month between 
Jan 1, 2009, and Dec 31, 2014. We excluded about 
560 children admitted to hospital with bloody diarrhoea 
or diarrhoea caused by chronic opportunistic infections, 
which combined accounted for 2–3% of hospital 
admissions for all-cause diarrhoea per year and showed 
no clear seasonality. In the prevaccine years (2009–11) at 
these hospitals, we recorded a median of 4051 (min–max 
range 3347–4301) hospital admissions for diarrhoea in 
children younger than 5 years per year. We noted a strong 
seasonal pattern: more hospital admissions for diarrhoea 
coincided with the rotavirus season from May to 
September during each prevaccine year from 2009 to 
2011, with a peak in July (ﬁ gure 1). In 2013, the ﬁ rst 
full year after rotavirus vaccine introduction, hospital 
admissions for diarrhoea in children younger than 5 years 
fell by 29% to 2881 admissions, and in 2014, decreased by 
17% to 3371, compared with the prevaccine introduction 
median. Compared with the predicted number of hospital 
admissions for diarrhoea from the time-series model, the 
recorded number was 21% (95% CI –2 to 39) lower in 
2013 and 4% (–32 to 30) lower in 2014 (ﬁ gure 2). We noted 
signiﬁ cant seasonality during April to September. When 
we restricted the analysis to these months, the number of 
hospital admissions for diarrhoea was 40% (95% CI 
17 to 56) lower in 2013, and 27% (–9 to 51) lower in 2014, 
compared with the predicted number of admissions. In 
both 2013 and 2014, the fall in hospital admissions for 
Figure 2: Total hospital and acute gastroenteritis admissions and proportion of total hospital admissions for 
diarrhoea in children at four district and two teaching hospitals, 2009–14
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diarrhoea was restricted to the rotavirus season months 
from May to September (ﬁ gure 1). Between May and 
September, the median number of hospital admissions 
for diarrhoea during the prevaccine period 2009–11 was 
2506; this number declined by 47% (N=1333) in 2013 and 
by 39% (N=1539) in 2014.
In our review of registries from the paediatric 
admission wards at four large district hospitals and 
two referral teaching hospitals, the proportion of total 
hospital admissions for diarrhoea in 2013 and 2014 in all 
age groups signiﬁ cantly decreased from the median 
prevaccine baseline (p<0·01 for each age group for 
each year; appendix). In the prevaccine era, a median of 
9784 (min–max range  8225–10 462) hospital admissions 
were recorded per year in children younger than 5 years. 
Of these, a median of 1968 (min–max range 1572–1994) 
admissions (19%, 19–20%) were due to diarrhoea 
(ﬁ gure 2). Compared with the prevaccine median from 
2009–11, the number of hospital admissions for diarrhoea 
in children younger than 5 years fell by 49% to 
1004 admissions in 2013 and by 48% to 1030 in 2014, 
accounting for 12% and 13% of total admissions in the 
2 post-vaccine years, respectively (ﬁ gure 3). 
Of children younger than 1 year, the prevaccine 
median number of total hospital admissions was 
4257 (range 3835–4999) and of these, a median of 
1044 (range 790–1183) were due to diarrhoea (ie, 21–25% 
of total hospital admissions; ﬁ gure 2). The number of 
hospital admissions for diarrhoea in children younger 
than 1 year decreased by 55% to 466 in 2013, and by 51% 
to 508 in 2014, compared with the prevaccine baseline, 
accounting for 12% and 13% of total hospital admissions 
in the 2 post-vaccine years, respectively (ﬁ gure 3). 
Similarly in children aged 1–4 years, we noted a pre-
vaccine median of 5463 (min–max range 4390–5527) 
total hospital admissions and, of these, a median of 
785 (782–950) due to diarrhoea, accounting for 14–18% 
of total admissions in this age group (ﬁ gure 2). The 
number of hospital admissions for diarrhoea in children 
aged 1–4 years fell by 31% to 538 in 2013, and by 34% to 
522 in 2014, compared with the prevaccine baseline, 
accounting for 11% and 12% of total admissions in the 
2 post-vaccine years, respectively (ﬁ gure 3). The seasonal 
peak was blunted in all age groups after vaccine 
introduction.
With regard to trends in rotavirus-speciﬁ c hospital 
admissions and changes in rotavirus epidemiology, one 
sentinel hospital located in eastern province undertook 
active surveillance for rotavirus continuously from January, 
2011, to December, 2014 (ﬁ gure 4). The number of rotavirus 
detections increased from May to September of each year. 
After the introduction of rotavirus vaccine in May, 2012, 
the annual peak in admittances to hospital because of 
rotavirus in eastern province was blunted in 2013 and 2014, 
with a 61% and 70% fall in the number of admissions 
because of rotavirus in 2013 and 2014, respectively, 
compared with the prevaccine year of 2011 (p=0·04).
Using data from all eight surveillance hospitals, the 
proportion of children younger than 5 years admitted to 
hospital for diarrhoea caused by rotavirus fell from 52% in 
2011, to 24% in 2013 (p<0·0001) and 23% in 2014 
(p<0·0001). This decrease in the proportion of hospital 
admissions for diarrhoea that were rotavirus-positive was 
noted across almost all age groups, but the greatest eﬀ ect 
was recorded in children directly protected by the vaccine 
(children aged 3–11 months in 2013, and 3–23 months in 
2014; ﬁ gure 5). In 2011, 56% (74/133) of all admittances to 
hospital because of rotavirus happened in children younger 
Figure 3: Median and range (min–max) of the number of acute gastroenteritis hospital admissions 
by month before vaccine introduction (2009–11) and in 2013 and 2014 in children at four district and two 
teaching hospitals
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than 1 year. In 2013, the cumulative age distribution shifted 
to the right, with 31% (58/185) of rotavirus hospital 
admissions happening before the age of 1 year. In 2014, 
37 (36%) of 103 of hospital admissions because of rotavirus 
happened in children younger than 1 year.
Discussion
As an early introducer of rotavirus vaccine into its 
expanded programme on immunisation, Rwanda is one 
of the ﬁ rst low-income countries in sub-Saharan Africa 
to document the eﬀ ect of rotavirus vaccine and the ﬁ rst 
to assess RV5. The introduction of the rotavirus vaccine 
resulted in rapid and substantial reductions in 
admissions to hospital for acute, non-bloody diarrhoea, 
and for rotavirus in children younger than 5 years. 
Similar to other countries with seasonal rotavirus 
disease, Rwanda observed a signiﬁ cant blunting in the 
seasonal peaks of hospital admissions for diarrhoea after 
the introduction of rotavirus vaccine into the national 
expanded programme on immunisation. We noted the 
biggest eﬀ ect in children age-eligible to be vaccinated, 
resulting in a shift of the age distribution of hospital 
admissions for rotavirus to older-age children 
immediately after rotavirus vaccine introduction. 
However, a decrease in the proportion of children with 
diarrhoea testing positive for rotavirus was recorded in 
almost every age group, including children too young 
and too old to be vaccinated; this decrease might suggest 
that these children are indirectly protected by the vaccine 
through reduced transmission of rotavirus in the 
population.
Findings of the assessment of vaccine eﬀ ectiveness after 
the introduction of RV1 into the routine immunisation 
programmes in South Africa and Malawi showed that the 
vaccine was 57–64% eﬀ ective against hospital admissions 
for rotavirus and reduced the prevalence of rotavirus in 
young children.50–52 We report the ﬁ rst data for the eﬀ ect of 
routine RV5 vaccination in Africa. The strong seasonal 
peaks in hospital admissions for diarrhoea combined with 
a high rotavirus detection rate in the prevaccine period 
help accentuate the eﬀ ect of the vaccine, as most of the 
reduction in diarrheal disease happened during these 
seasonal peaks. The fall in hospital admissions for 
diarrhoea noted in Rwanda is similar to decreases 
recorded in Brazil, Mexico, and Panama, and the decreased 
hospital admissions for rotavirus are similar to those 
reported in Brazil and El Salvador after the implementation 
of rotavirus vaccine  in these countries.7,26–30
We noted a greater reduction in the number of hospital 
admissions for diarrhoea in 2013 compared with 2014. 
This phenomenon of alternating years of larger and 
smaller reductions has been recorded over 7 post-
introduction years in the USA and is probably the result 
of the accumulation of susceptible children over 
successive seasons resulting in increased transmission.53,54 
With only 2 years of post-vaccine data from Rwanda, it is 
too early to establish whether such a pattern is happening 
in this high disease burden setting, but continued 
monitoring of trends in hospital admissions for diarrhoea 
in the post-vaccination era will provide data to study this 
trend. Finally, indirect protection of children too old to 
have been vaccinated with rotavirus vaccine has been 
previously reported in several high-income and middle-
income countries including the USA, Australia, Austria, 
and El Salvador.23,24,26,55–58 We provide the ﬁ rst possible 
evidence of indirect protection from rotavirus vaccination 
in a high-burden, low-income setting.
Figure 4: Rotavirus detections by month in children aged <5 years admitted to one district hospital, January, 
2011–December, 2014
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This study has some limitations. First, the Health 
Management Information System was strengthened and 
expanded in January, 2012, immediately before rotavirus 
vaccine introduction in May, 2012. Additional hospitals 
began reporting to the system. To maintain comparability 
between 2009 and 2014, we restricted the analyses to 
district hospitals that were included in both 2009–11 and 
2012–14 and that reported the number of hospital 
admissions for diarrhoea to the Health Management 
Information System every month from January, 2009, to 
December, 2014. The strengthening of the system could 
have resulted in more complete reporting during the post-
vaccine era, which would have lowered the estimates of 
vaccine eﬀ ect. To further validate our results, we compared 
two district hospitals that had both Health Management 
Information System data and data from the registry review 
and noted that both data sources showed similar trends in 
diarrhoea disease during the 6 year time period (appendix). 
Second, hospital admissions for diarrhoea for the Health 
Management Information System analysis and the 
registry review were based on hospital admissions deﬁ ned 
as related to diarrhoea at the site level rather than based on 
a standardised national case deﬁ nition, and some 
variability could have existed between hospitals. However, 
for each analysis we captured a standard set of discharge 
diagnoses for diarrhoea and acute gastroenteritis. Third, 
we excluded bloody and chronic diarrhoea from the 
Health Management Information System analysis; 
however, this process probably had little eﬀ ect on our 
results because bloody and chronic diarrhoea accounted 
for only 2–3% of hospital admissions for diarrhoea 
every year and showed no trends in seasonality. Finally, we 
only had 1 complete year of active rotavirus surveillance 
from one site before vaccine introduction. However, this 
site enrolled more than 150 children admitted to hospital 
for diarrhoea before vaccine introduction and so was able 
to provide a stable baseline. Furthermore, despite their 
individual limitations, the compatibility in trends recorded 
across the three surveillance platforms is reassuring that 
these platforms were probably internally consistent over 
time and provide additional conﬁ dence in our ﬁ ndings. 
The sharp decrease in hospital admissions for diarrhoea, 
with the largest eﬀ ect recorded in children age-eligible to 
be vaccinated and which occurred coincident with the 
introduction of rotavirus vaccine, suggests that the 
decrease in hospital admissions for diarrhoea during this 
period is the result of the introduction of rotavirus vaccine 
and not incremental improvements in sanitation, hygiene, 
or clean water. By 2013, three-dose rotavirus vaccine 
coverage in children younger than 1 year was estimated to 
reach 99% and remained high at 98% in 2014.54
In summary, hospital admissions for diarrhoea and 
rotavirus in Rwanda decreased substantially after 
rotavirus vaccine implementation. We noted decreases 
not only in children who were eligible to be vaccinated, 
but also in children age-ineligible to have received the 
vaccine, suggesting that these children were indirectly 
protected through reduced transmission of rotavirus in 
the population. These data support the continued use of 
rotavirus vaccine in Rwanda and highlight the beneﬁ ts 
of routine vaccination against rotavirus in low-income 
settings.
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